Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. - ROEverified

SUPN

Price:

$44.38

Market Cap:

$2.58B

Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to ...[Read more]

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

2012-05-01

Stock Exchange

NASDAQ

Ticker

SUPN

The ROE as of June 2026 (TTM) for Supernus Pharmaceuticals, Inc. (SUPN) is -2.73%

According to Supernus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -2.73%. This represents a change of 292.32% compared to the average of -0.70% of the last 4 quarters.

Supernus Pharmaceuticals, Inc. (SUPN) Historical ROE (quarterly & annually)

How has SUPN ROE performed in the past?

The mean historical ROE of Supernus Pharmaceuticals, Inc. over the last ten years is 14.66%. The current -2.73% ROE has changed -118.62% with respect to the historical average. Over the past ten years (40 quarters), SUPN's ROE was at its highest in in the September 2016 quarter at 35.66%. The ROE was at its lowest in in the September 2025 quarter at -4.30%.

Quarterly (TTM)
Annual

Average

14.66%

Median

12.09%

Minimum

-3.63%

Maximum

47.57%

Supernus Pharmaceuticals, Inc. (SUPN) ROE by Quarter and Year

Discovering the peaks and valleys of Supernus Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 4.89%

Maximum Annual ROE = 47.57%

Minimum Annual Increase = -150.91%

Minimum Annual ROE = -3.63%

Quarterly (TTM)
Annual
YearROEChange
2025-3.63%-150.91%
20247.13%4.89%
20230.14%-97.92%
20226.85%4.62%
20216.55%-61.58%
202017.04%-10.24%
201918.99%-22.50%
201824.50%14.40%
201721.42%-54.98%
201647.57%303.47%

Supernus Pharmaceuticals, Inc. (SUPN) Average ROE

How has SUPN ROE performed in the past?

The current ROE of Supernus Pharmaceuticals, Inc. (SUPN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

1.21%

5-year avg

3.41%

10-year avg

14.66%

Supernus Pharmaceuticals, Inc. (SUPN) ROE vs. Peers

How is SUPN’s ROE compared to its peers?

Supernus Pharmaceuticals, Inc.’s ROE is less than HUTCHMED (China) Limited (37.04%), greater than Perrigo Company plc (-50.65%), greater than Xenon Pharmaceuticals Inc. (-49.23%), greater than Indivior Pharmaceuticals Inc (-142.01%), less than Bausch Health Companies Inc. (120.75%), greater than Amneal Pharmaceuticals, Inc. (-144.72%), less than Lantheus Holdings, Inc. (24.33%), greater than Centessa Pharmaceuticals plc (-60.37%), greater than GRAIL, Inc. (-16.42%), greater than CG Oncology, Inc. Common stock (-23.33%),

Build a custom stock screener for Supernus Pharmaceuticals, Inc. (SUPN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Supernus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Supernus Pharmaceuticals, Inc. (SUPN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Supernus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Supernus Pharmaceuticals, Inc.'s ROE?

How is the ROE calculated for Supernus Pharmaceuticals, Inc. (SUPN)?

What is the highest ROE for Supernus Pharmaceuticals, Inc. (SUPN)?

What is the 3-year average ROE for Supernus Pharmaceuticals, Inc. (SUPN)?

What is the 5-year average ROE for Supernus Pharmaceuticals, Inc. (SUPN)?

How does the current ROE for Supernus Pharmaceuticals, Inc. (SUPN) compare to its historical average?